{
  "abstract": "This case highlights the use of intravenous immunoglobulin (IVIG) in a patient with refractory pure class V lupus nephritis (LN), a challenging subtype of LN. A woman in her 30s with systemic lupus erythematosus developed severe proteinuria and could not tolerate standard immunosuppressants due to life-threatening infections. IVIG, though not a guideline-recommended therapy for class V LN, was initiated as an alternative. Over a 6-month period, the urinary protein-to-creatinine ratio decreased significantly, resulting in sustained renal remission. IVIG’s mechanism involves modulating immunity, neutralising autoantibodies and reducing inflammation with a favourable safety profile compared with glucocorticoids and mycophenolate. While the current literature lacks robust trials, case reports and limited studies suggest that IVIG has the potential to treat difficult-to-treat LN. This case highlights the potential role of IVIG in LN and advocates for further research to establish its efficacy in managing class V LN, particularly in patients unable to tolerate conventional therapies.",
  "authors": [
    {
      "affiliations": [
        "Rheumatology, Montefiore Medical Center, New York, New York, USA"
      ],
      "name": "Chen Chao"
    },
    {
      "affiliations": [
        "Albert Einstein College of Medicine, New York, New York, USA"
      ],
      "name": "Jessica Weinberg"
    },
    {
      "affiliations": [
        "Department of Pathology, Montefiore Medical Center, New York, New York, USA"
      ],
      "name": "James M Pullman"
    },
    {
      "affiliations": [
        "Rheumatology, Montefiore Medical Center, New York, New York, USA"
      ],
      "name": "Clement E Tagoe"
    }
  ],
  "title": "Patient with class V lupus nephritis (LN) treated with intravenous immunoglobulin (IVIG) achieving a favourable outcome",
  "uid": "193b4b03-6678-5f3f-8f06-042ad182ff03"
}